

Name of Journal: *World Journal of Hepatology*

Manuscript NO: 66613

Manuscript Type: MINIREVIEWS

Elastography as predictor of liver cirrhosis complications after Hepatitis C virus eradication in the era of direct-acting antivirals

Cerrito L *et al.* Elastography and liver related events

Lucia Cerrito, Maria Elena Ainora, Alberto Nicoletti, Matteo Garcovich, Laura Riccardi, Maurizio Pompili, Antonio Gasbarrini, Maria Assunta Zocco

Match Overview



1	Crossref 98 words Luca Miele, Maria A. Zocco, Fabrizio Pizzolante, Nicoletta D e Matthaeis et al. "Use of imaging techniques for non-invas...	2%
2	Crossref 24 words Ping-Hsien Chen, Wei-Yao Hsieh, Chien-Wei Su, Ming-Chih Hou et al. "Combination of albumin-bilirubin grade and platel	<1%
3	Internet 23 words crawled on 08-Apr-2021 atm.amegroups.com	<1%
4	Internet 21 words crawled on 02-Sep-2019 www.tandfonline.com	<1%
5	Internet 17 words crawled on 23-Jul-2021 www.jcancer.org	<1%
6	Crossref 12 words "Posters (Abstracts 264-2239)", <i>Hepatology</i> , 2017	<1%
7	Crossref 12 words K. Neukam, L. E. Morano-Amado, A. Rivero-Juárez, J. Mací as et al. "Liver stiffness predicts the response to direct-actin	<1%

ALL

IMAGES

VIDEOS

12,200 Results

Any time ▼

Liver function following hepatitis C virus eradication by ...

<https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06053-3> ▼

May 04, 2021 · **Hepatitis C Virus (HCV) eradication** by direct-acting **antivirals (DAA)** is linked to improved outcomes at all stages **of liver** disease . Available data suggest that the maximum efficacy and benefits are obtained by treating patients before they reach the stage of advanced fibrosis or **cirrhosis** [2 , 3].

Author: Maria Giovanna Quaranta, Luigina Ferri... **Publish Year:** 2021

Liver steatosis and dyslipidemia after HCV eradication by ...

<https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0209615> ▼

Dec 21, 2018 · Aim We comprehensively analyzed how **hepatitis C virus (HCV) eradication** by interferon (IFN)-free direct-acting-antiviral-agents (DAAs) affects **liver** steatosis and atherogenic risk. Methods Patients treated with IFN-free-DAAs who underwent transient **elastography** before and at 24-weeks post-treatment, including controlled attenuation parameter (CAP), and achieved sustained viral response ...

Cited by: 12 **Author:** Naoki Kawagishi, Goki Suda, Akinobu Naka...

Publish Year: 2018

Short-term histological evaluations after achieving a ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206535>

Jul 19, 2018 · An estimated 71 million people are chronically infected with **hepatitis C virus (HCV)** worldwide, and approximately 399,000 people die annually from **hepatitis C**-related causes, including mainly **cirrhosis** and hepatocellular carcinoma (HCC). 1 A sustained virologic response (SVR) is merely a surrogate marker for the virologic cure of HCV infection, and the ultimate goal of anti-HCV treatments is to prevent the development of **cirrhosis** and its **complications**...

Cited by: 12 **Author:** Masaru Enomoto, Yoshihiro Ikura, Akihiro T...

Publish Year: 2018

Impact of hepatitis C oral therapy in portal hypertension

Search Tools

Turn off Hover Translation (关闭取词)

12,200 Results Any time ▾

Short-term risk of hepatocellular carcinoma after ...

<https://pubmed.ncbi.nlm.nih.gov/29035002>

Background: With the development of **direct-acting anti-virals** (DAAs), almost all patients with chronic **hepatitis C virus** (HCV) infection can achieve sustained viral response (SVR). Aim: To evaluate the short-term risk of HCC among patients with SVR by DAAs, including those with **cirrhosis** or previous HCC. Methods: This large-scale, multicentre cohort study included 1,675 consecutive patients ...

Cited by: 82 **Author:** E. Ogawa, N. Furusyo, H. Nomura, K. Dohm...

Publish Year: 2018

Liver steatosis and dyslipidemia after HCV eradication by ...

<https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0209615> ▾

Dec 21, 2018 · Aim We comprehensively analyzed how **hepatitis C virus** (HCV) **eradication** by interferon (IFN)-free **direct-acting-antiviral-agents** (DAAs) affects **liver** steatosis and atherogenic risk. Methods Patients treated with IFN-free-DAAs who underwent transient **elastography** before and at 24-weeks post-treatment, including controlled attenuation parameter (CAP), and achieved sustained viral response ...

Cited by: 12 **Author:** Naoki Kawagishi, Goki Suda, Akinobu Naka...

Publish Year: 2018

Liver function following hepatitis C virus eradication by ...

<https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06053-3> ▾

May 04, 2021 · **Hepatitis C Virus** (HCV) **eradication** by **direct-acting antivirals** (DAA) is linked to improved outcomes at all stages of **liver** disease [1]. Available data suggest that the maximum efficacy and benefits are obtained by treating patients before they reach the stage of advanced fibrosis or **cirrhosis** [2, 3]. Sustained virologic response (SVR) reduces the risk of **liver** decompensation and of ...

Cited by: 1 **Author:** Maria Giovanna Quaranta, Luigina Ferrigno,...

Publish Year: 2021

Short-term histological evaluations after achieving a ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206535>


Jul 19, 2018 · An estimated 71 million people are chronically infected with **hepatitis C virus** (HCV) worldwide, and approximately 399,000 people die annually from **hepatitis C**-related causes, including mainly **cirrhosis** and hepatocellular carcinoma (HCC). 1 A sustained virologic response (SVR) is merely a surrogate marker for the virologic cure of HCV infection, and the ultimate goal of anti-HCV treatments is to prevent the development of **cirrhosis** and its **complications**...

Cited by: 12 **Author:** Masaru Enomoto, Yoshihiro Ikura, Akihiro T...

Publish Year: 2018

Hepatitis C

Medical Condition



A viral infection that causes inflammation of liver that leads to liver inflammation.

🏠 Common (More than 200,000 cases per year in US)

👤 Transmitted through blood contact

🧪 Often requires lab test or imaging

🩺 Treatable by a medical professional

🕒 Can last several months or years

It is caused by a blood borne hepatitis C virus and commonly transmitted through blood. Most of the people show no symptoms or experience a mild illness which may include fatigue, abdominal pain, loss of appetite, nausea or yellow discoloration of eyes and skin. Although no vaccine for hepatitis C is available. Medicines can cure most cases of hepatitis C. A combination of antiviral medications are prescribed depending on the genotype of the virus, viral load and presence of any liver damage.

Symptoms

During the acute phase (first 6 months after infection) most persons show no symptoms or might experience a mild illness. During the chronic phase the symptoms include:

• jaundice (yellow discoloration of the skin and eyes)